Clinical Trials Directory

Trials / Unknown

UnknownNCT04122820

Ambulatory Screening for Specific Learning Disabilities (SLD) and Developmental Coordination Disorder (DCD).

Sensitivity of the Search for a Heterophory-Vertical-Labile (HV-Labile) for Ambulatory Screening for Specific Learning Disabilities (SLD) or Developmental Coordination Disorder (DCD).

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,800 (estimated)
Sponsor
CNGE IRMG Association · Academic / Other
Sex
All
Age
8 Years – 12 Years
Healthy volunteers
Not accepted

Summary

To evaluate, in primary care, the sensitivity of Heterophory-Vertical-Labile (HV-Labile) in ambulatory screening for Specific Learning Disabilities (SLD) and Developmental Coordination Disorder (DCD). in children aged 8 to 12 years.

Detailed description

General practitioners during a day of professional training on learning disabilities will be trained to perform the proprioceptive Maddox, to search for a HVLabile. Each trained practitioner will then test at least six children aged 8 to 12 years old in his or her practice, seen at random 250 to 300 physicians will be trained as part of this research EXPERIMENTAL DESIGN * Cross-sectional study with prospective recruitment. * Search for a Vertical Labile Heterophory (HV-Labile). * Prescription of a standardized speech and language screening assessment for HV-Labile, and in the same number of children without HV-Labile by secondary coupling. * Delivery of symptomatic questionnaire. * In case of learning disabilities, the attending physician should look for a possible etiology. * Adapted speech therapy care for more than six months. * Speech and language therapy check-up at more than six months.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTDiagnostic of specific learning disabilities or of Developmental Coordination DisorderSpeech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.

Timeline

Start date
2019-10-16
Primary completion
2021-10-30
Completion
2022-10-30
First posted
2019-10-10
Last updated
2019-10-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04122820. Inclusion in this directory is not an endorsement.